Boston Medical Center Corporation
UEI JZ8RQC4EMDZ5 · MA · SAM.gov record ↗
Obligations by agency
- Department Of Health And Human Services$795K
- Department Of Veterans Affairs$527K
Obligations by NAICS
Monthly obligations
Contracts ending within 18 months (recompete watch)
- 75D30123F00001 ↗$218K
2023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQ
- Ends
- Sep 26, 2026
- Started
- Sep 27, 2023
- Agency
- Centers For Disease Control And Prevention
- NAICS
- 622110
- 36C24126C0007 ↗$127K
OPHTHALMOLOGY PHYSICIAN SERVICES
- Ends
- Jan 30, 2027
- Started
- Jan 31, 2026
- Agency
- Department Of Veterans Affairs
- NAICS
- 611310
- 75N94025F00001 ↗$600K
NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE
- Ends
- Dec 30, 2027
- Started
- Jul 31, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75D30123F00001 ↗ | 2023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQ | Centers For Disease Control And Prevention | 622110 | $218K | Sep 27, 2023 | Sep 26, 2026 |
| 36C24126C0007 ↗ | OPHTHALMOLOGY PHYSICIAN SERVICES | Department Of Veterans Affairs | 611310 | $127K | Jan 31, 2026 | Jan 30, 2027 |
| 75N94025F00001 ↗ | NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE | National Institutes Of Health | 541714 | $600K | Jul 31, 2025 | Dec 30, 2027 |
Largest awards
- 75N94025F00001 ↗$600K
NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE
- Ends
- Dec 30, 2027
- Started
- Jul 31, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541714
- 36C24125C0070 ↗$350K
EDUCATION COST SHARING
- Ends
- Jun 29, 2030
- Started
- Sep 23, 2025
- Agency
- Department Of Veterans Affairs
- NAICS
- 611310
- 75D30123F00001 ↗$218K
2023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQ
- Ends
- Sep 26, 2026
- Started
- Sep 27, 2023
- Agency
- Centers For Disease Control And Prevention
- NAICS
- 622110
- 36C24126C0007 ↗$127K
OPHTHALMOLOGY PHYSICIAN SERVICES
- Ends
- Jan 30, 2027
- Started
- Jan 31, 2026
- Agency
- Department Of Veterans Affairs
- NAICS
- 611310
- 36C24124C0086 ↗$50K
ONSITE OPHTHALMOLOGY SERVICES
- Ends
- Jan 30, 2026
- Started
- Jul 31, 2024
- Agency
- Department Of Veterans Affairs
- NAICS
- 611310
NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE
- Ends
- Jul 13, 2026
- Started
- Sep 23, 2018
- Agency
- National Institutes Of Health
- NAICS
- 622310
EDUCATION COSTS
- Ends
- Jun 29, 2026
- Started
- Jun 30, 2021
- Agency
- Department Of Veterans Affairs
- NAICS
- 622110
NICHD: R&D: TO CONDUCT PHASE I, II, III OR IV CONTRACEPTIVE TRIALS IN WOMEN, TREATMENT TRIALS OF GYNECOLOGIC CONDITIONS SUCH AS ENDOMETRIOSIS OR LEIOMYOMATA, AND DEVELOPMENT OF RESEARCH PROTOCOLS ON A TASK ORDER BASIS: NON-SEVERABLE
- Ends
- —
- Started
- Jul 31, 2020
- Agency
- National Institutes Of Health
- NAICS
- 541714
- 75N94020F00001 ↗$-11K
TO ASSIST IN THE DEVELOPMENT OF NEW CONTRACEPTIVE PRODUCTS BY PROVIDING SERVICES RELATED TO PROTOCOL REVIEW, PROTOCOL DEVELOPMENT AND ACTIVITIES ASSOCIATED WITH PAST, PRESENT AND FUTURE CCTN ACTIVITIES.
- Ends
- Jul 30, 2026
- Started
- Jul 31, 2020
- Agency
- National Institutes Of Health
- NAICS
- 541714
- 75N94023F00001 ↗$-13K
NICHD: R&D: OVAPRENE VAGINAL DEVICE CLINICAL TRIAL: NON-SEVERABLE FY22 CAN 8054183
- Ends
- Feb 27, 2026
- Started
- Sep 27, 2023
- Agency
- National Institutes Of Health
- NAICS
- 541714
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N94025F00001 ↗ | NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE | National Institutes Of Health | 541714 | $600K | Jul 31, 2025 | Dec 30, 2027 |
| 36C24125C0070 ↗ | EDUCATION COST SHARING | Department Of Veterans Affairs | 611310 | $350K | Sep 23, 2025 | Jun 29, 2030 |
| 75D30123F00001 ↗ | 2023 CLINICAL IMMUNIZATION SAFETY ASSESSMENT (CISA) BASE IDIQ | Centers For Disease Control And Prevention | 622110 | $218K | Sep 27, 2023 | Sep 26, 2026 |
| 36C24126C0007 ↗ | OPHTHALMOLOGY PHYSICIAN SERVICES | Department Of Veterans Affairs | 611310 | $127K | Jan 31, 2026 | Jan 30, 2027 |
| 36C24124C0086 ↗ | ONSITE OPHTHALMOLOGY SERVICES | Department Of Veterans Affairs | 611310 | $50K | Jul 31, 2024 | Jan 30, 2026 |
| 75N94018F00003 ↗ | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE | National Institutes Of Health | 622310 | $0 | Sep 23, 2018 | Jul 13, 2026 |
| 36C24121C0047 ↗ | EDUCATION COSTS | Department Of Veterans Affairs | 622110 | $0 | Jun 30, 2021 | Jun 29, 2026 |
| 75N94020D00004 ↗ | NICHD: R&D: TO CONDUCT PHASE I, II, III OR IV CONTRACEPTIVE TRIALS IN WOMEN, TREATMENT TRIALS OF GYNECOLOGIC CONDITIONS SUCH AS ENDOMETRIOSIS OR LEIOMYOMATA, AND DEVELOPMENT OF RESEARCH PROTOCOLS ON A TASK ORDER BASIS: NON-SEVERABLE | National Institutes Of Health | 541714 | $0 | Jul 31, 2020 | — |
| 75N94020F00001 ↗ | TO ASSIST IN THE DEVELOPMENT OF NEW CONTRACEPTIVE PRODUCTS BY PROVIDING SERVICES RELATED TO PROTOCOL REVIEW, PROTOCOL DEVELOPMENT AND ACTIVITIES ASSOCIATED WITH PAST, PRESENT AND FUTURE CCTN ACTIVITIES. | National Institutes Of Health | 541714 | $-11K | Jul 31, 2020 | Jul 30, 2026 |
| 75N94023F00001 ↗ | NICHD: R&D: OVAPRENE VAGINAL DEVICE CLINICAL TRIAL: NON-SEVERABLE FY22 CAN 8054183 | National Institutes Of Health | 541714 | $-13K | Sep 27, 2023 | Feb 27, 2026 |